.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Merck
Julphar
Mallinckrodt
Fish and Richardson
Baxter
Moodys
Argus Health
Healthtrust
Harvard Business School
Daiichi Sankyo

Generated: September 23, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 5,873,360 protect, and when does it expire?


Patent ► Subscribe protects FLOVENT DISKUS 100, FLOVENT DISKUS 250, FLOVENT DISKUS 50, ADVAIR DISKUS 100/50, ADVAIR DISKUS 250/50, ADVAIR DISKUS 500/50, and SEREVENT, and is included in three NDAs.

Protection for FLOVENT DISKUS 100 has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has seventy-eight patent family members in forty-one countries.

Summary for Patent: ► Subscribe

Title: Inhalation device
Abstract:An inhalation device is described for use with a medicament pack in which at least one container for medicament in powder form is defined between two sheets peelably secured to one another. The device comprises means for peeling the sheets apart at an opening station to open the container; and an outlet, communicating with the opened container, through which a user can inhale medicament in powder form from the opened container.
Inventor(s): Davies; Michael Birsha (Ware, GB2), Hearne; David John (Luton, GB2), Rand; Paul Kenneth (Letchworth, GB2), Walker; Richard Ian (Ware, GB2)
Assignee: Glaxo Group Limited (London, GB2)
Application Number:08/467,469
Patent Claim Types:
see list of patent claims
Device;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Glaxo Grp Ltd
FLOVENT DISKUS 100
fluticasone propionate
POWDER;INHALATION020833-002Sep 29, 2000RXYesYes► Subscribe► Subscribe
Glaxo Grp Ltd
FLOVENT DISKUS 250
fluticasone propionate
POWDER;INHALATION020833-003Sep 29, 2000RXYesYes► Subscribe► Subscribe
Glaxo Grp Ltd
FLOVENT DISKUS 50
fluticasone propionate
POWDER;INHALATION020833-001Sep 29, 2000RXYesYes► Subscribe► Subscribe
Glaxo Grp Ltd
ADVAIR DISKUS 100/50
fluticasone propionate; salmeterol xinafoate
POWDER;INHALATION021077-001Aug 24, 2000RXYesYes► Subscribe► Subscribe
Glaxo Grp Ltd
ADVAIR DISKUS 250/50
fluticasone propionate; salmeterol xinafoate
POWDER;INHALATION021077-002Aug 24, 2000RXYesYes► Subscribe► Subscribe
Glaxo Grp Ltd
ADVAIR DISKUS 500/50
fluticasone propionate; salmeterol xinafoate
POWDER;INHALATION021077-003Aug 24, 2000RXYesYes► Subscribe► Subscribe
Glaxosmithkline
SEREVENT
salmeterol xinafoate
POWDER;INHALATION020692-001Sep 19, 1997RXYesYes► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: ► Subscribe

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom90 04781Mar 02, 1990

Non-Orange Book Patents for Patent: ► Subscribe

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
2,006,107,948► Subscribe
6,032,666 Inhalation device► Subscribe
5,860,419 Inhalation device► Subscribe
5,590,645 Inhalation device► Subscribe
7,389,775Inhalation device► Subscribe
6,792,945 Inhalation device► Subscribe
7,225,808Inhalation device► Subscribe
2,007,107,724► Subscribe
6,536,427 Inhalation device► Subscribe
6,378,519 Inhalation device► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Israel97396► Subscribe
Czech Republic283168► Subscribe
Czech Republic9601807► Subscribe
Czech Republic285501► Subscribe
Germany4106379► Subscribe
Denmark37991► Subscribe
Denmark175075► Subscribe
Spain2031763► Subscribe
Finland911037► Subscribe
Finland107883► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Teva
Citi
Baxter
Novartis
Deloitte
Cantor Fitzgerald
UBS
Covington
Boehringer Ingelheim
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot